The Francis Crick Institute, London, UK.
Immunol Rev. 2023 Jan;313(1):217-224. doi: 10.1111/imr.13165. Epub 2022 Nov 21.
The C3 "Tickover" hypothesis, a mechanism whereby the host maintains constant surveillance of potential invading pathogens, targeting them for elimination through amplified C3b generation and C3-dependent effector mechanisms, was proposed by the late Professor Peter Lachmann in 1973. This unique insight came from a combined understanding of the complement system as it was then defined and the nature of the disease process in rare complement deficiencies and complement-driven diseases. In this review, I give a personal perspective of how understanding of "Tickover" has developed in the subsequent 50 years, culminating in the introduction into the clinic of therapeutic agents designed to combat amplification-driven disease.
C3“怠速”假说,一种宿主通过扩增 C3b 生成和 C3 依赖性效应机制来对潜在入侵病原体进行持续监测并将其靶向消除的机制,由已故教授 Peter Lachmann 于 1973 年提出。这一独特的见解源于对当时定义的补体系统和罕见补体缺陷和补体驱动疾病的疾病过程的综合理解。在这篇综述中,我从个人角度介绍了在随后的 50 年中对“怠速”的理解是如何发展的,最终引入了旨在对抗放大驱动疾病的治疗药物。